NASDAQ:CSCI - Nasdaq - CA22112H1010 - Common Stock - Currency: USD
NASDAQ:CSCI (2/21/2025, 8:11:02 PM)
2.72
-0.02 (-0.91%)
The current stock price of CSCI is 2.72 USD. In the past month the price decreased by -5.39%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
COSCIENS BIOPHARMA INC
C/O Norton Rose Fulbright Canada Llp, 222 Bay Street, Suite 3000, Po Box 53
TORONTO ONTARIO CA
Employees: 21
Company Website: https://www.zentaris.com/
Investor Relations: http://ir.aezsinc.com/
Phone: 18439003201
The current stock price of CSCI is 2.72 USD. The price decreased by -0.91% in the last trading session.
The exchange symbol of COSCIENS BIOPHARMA INC is CSCI and it is listed on the Nasdaq exchange.
CSCI stock is listed on the Nasdaq exchange.
COSCIENS BIOPHARMA INC (CSCI) has a market capitalization of 10.28M USD. This makes CSCI a Nano Cap stock.
COSCIENS BIOPHARMA INC (CSCI) currently has 21 employees.
COSCIENS BIOPHARMA INC (CSCI) has a support level at 2.65 and a resistance level at 2.75. Check the full technical report for a detailed analysis of CSCI support and resistance levels.
The Revenue of COSCIENS BIOPHARMA INC (CSCI) is expected to decline by -2.27% in the next year. Check the estimates tab for more information on the CSCI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CSCI does not pay a dividend.
COSCIENS BIOPHARMA INC (CSCI) will report earnings on 2025-05-12.
COSCIENS BIOPHARMA INC (CSCI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11).
The outstanding short interest for COSCIENS BIOPHARMA INC (CSCI) is 0.06% of its float. Check the ownership tab for more information on the CSCI short interest.
ChartMill assigns a technical rating of 2 / 10 to CSCI.
ChartMill assigns a fundamental rating of 1 / 10 to CSCI. CSCI may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months CSCI reported a non-GAAP Earnings per Share(EPS) of -11. The EPS decreased by -274.15% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -32.47% | ||
ROE | -71.02% | ||
Debt/Equity | 0.06 |
ChartMill assigns a Buy % Consensus number of 83% to CSCI. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 68.75% and a revenue growth -2.27% for CSCI